Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.27 ^USD	+2.25%		+2.25%	+77.34%

Mar. 21	Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 21	Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Regulus Therapeutics Inc. Auditor Raises 'Going Concern' Doubt

March 08, 2021

Regulus Therapeutics Inc. filed its 10-K on Mar 09, 2021 for the period ending Dec 31, 2020. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Regulus Therapeutics Inc.

Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating	Mar. 19	MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target	Mar. 18	MT
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors	Mar. 13	CI
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating	Mar. 13	MT
Top Midday Gainers	Mar. 12	MT
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	Mar. 12	MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	Mar. 12	MT
Transcript : Regulus Therapeutics Inc. - Special Call	Mar. 12
Top Premarket Gainers	Mar. 12	MT
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Mar. 12	CI
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors	Mar. 10	CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	Jan. 02	CI
Transcript : Regulus Therapeutics Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:25 AM	Nov. 29
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Top Premarket Decliners	Nov. 09	MT
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Nov. 02	CI
Canaccord Genuity Raises Regulus Therapeutics' Price Target to $12 From $9, Keeps Buy Rating	23-09-21	MT
Transcript : Regulus Therapeutics Inc. - Special Call	23-09-20
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	23-09-13	CI
Transcript : Regulus Therapeutics Inc. - Special Call	23-09-06
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	23-06-27	CI
Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board	23-06-23	CI

Chart Regulus Therapeutics Inc.

Duration

Period

More charts

Company Profile

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.27 USD

Average target price

7.25 USD

Spread / Average Target

+219.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGULUS THERAPEUTICS INC.	+77.34%	145M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs